Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture.
about
What are we measuring? A critique of range of motion methods currently in use for Dupuytren's disease and recommendations for practiceIn vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related propertiesTrends in the Treatment of Dupuytren Disease in the United States Between 2007 and 2014.Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospectsIdentification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's ContractureFibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren's Contracture.Psychometric properties of health-related quality of life instruments in patients undergoing palmar fasciectomy for dupuytren's disease: a prospective study.Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.Surgical complications associated with fasciectomy for dupuytren's disease: a 20-year review of the English literature.Reversal of TGF-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts.The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease.Dupuytren's Disease: Review of the Current Literature.Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's diseaseInjectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroidsPrevalence, incidence, and treatments of Dupuytren's disease in the United States: results from a population-based studyUse of resources and costs associated with the treatment of Dupuytren's contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase clostridium hystolyticum versus subtotal fasciectomy.Collagenase clostridium histolyticum in patients with Dupuytren's contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes.Clinical Results of Percutaneous Needle Fasciotomy for Dupuytren's Disease in Japanese PatientsDelayed manipulation after collagenase clostridium histolyticum injection for Dupuytren contracture.Systematic review of non-surgical treatments for early dupuytren's disease.Minimally invasive partial fasciectomy for Dupuytren's contractures.Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.Increased CCT-eta expression is a marker of latent and active disease and a modulator of fibroblast contractility in Dupuytren's contracture.Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances.Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic reviewDupuytren's disease: current state of the artCollagenase clostridium histolyticum for Dupuytren's contracture.A systematic review of outcomes of fasciotomy, aponeurotomy, and collagenase treatments for Dupuytren's contracture.Early outcomes of a sequential series of 144 patients with Dupuytren's contracture treated by collagenase injection using an increased dose, multi-cord technique.Down-regulation of collagen synthesis and matrix metalloproteinase expression in myofibroblasts from Dupuytren nodule using adenovirus-mediated relaxin gene therapy.Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.Effects of Different Concentrations of Injectable Collagenase Enzyme on Capsular Tissue Around Silicone Implants: A Preliminary Experimental Study for the Development of a New Treatment Strategy.CORR® ORS Richard A. Brand Award: Clinical Trials of a New Treatment Method for Adhesive CapsulitisAdverse Effects of Collagenase in the Treatment of Dupuytren Disease: A Systematic Review.Molecular mechanisms and treatment strategies for Dupuytren's disease.Dupuytren's Contracture: A Bibliometric Study of the Most Cited Papers.Enhancement of the structural stability of full-length clostridial collagenase by calcium ions.Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture.A new bromelain-based enzyme for the release of Dupuytren's contracture: Dupuytren's enzymatic bromelain-based releaseEfficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: report of 40 cases.
P2860
Q28067091-A352D997-85DE-46E9-8058-FCA31999CBCEQ28481259-1B149D8B-DB4D-47F9-8F2A-E277494182F4Q30275011-358BD85F-B17B-4D39-BD9C-18A53E3FB27BQ30857029-150C63DA-BD07-4CB5-814B-7ADE6D265350Q33330485-5F874106-9E85-4A6B-9418-704A19D68B1AQ33353493-6653951C-74F3-4721-A367-7CADFB5AE653Q33619753-E2E37E6B-C648-4C5F-AC87-C45DF7CD6A0CQ33660754-A545701B-9BA1-4FC3-9348-106B104AB78DQ33686088-BE514900-706E-4152-85F3-F33F4E8E307FQ33911834-CA47D443-9DE7-4449-93A0-A2E845349C33Q34153159-CE477BB3-AE47-4952-B5B4-B3E57579FD02Q34212977-0F41458E-5776-48A8-BF03-0A7E68ABC68CQ34389581-CD07E21F-1A11-442F-8D5E-76309B81A829Q34506747-D6CB9926-E527-496D-AD0D-A9B9ED2CB8DEQ34975787-F515D570-A486-4480-B29D-28B78E88B230Q35017315-03254D05-B6ED-421E-9BDE-084B9DD39D59Q35181805-C6F6E5FB-2825-43F1-9DCE-EF4AD3025E5FQ35687675-40E069F9-ADD5-4ADD-94C1-4FDCCE7ECD98Q36001782-E3C2AB1E-9440-45DF-9E4E-0D8F1D3C8C83Q36104328-20544B9A-2401-4465-B8FB-53C3266E99D1Q36427744-09D8B530-C931-43E7-A2A2-C16A3CA79F65Q36799416-A4B18393-1F94-4222-A57C-E7E4961436A8Q36927329-7DEF21BD-AF0A-4645-955D-C32D8CF80529Q37300243-7084DC43-0C1A-475D-B504-33AA26AF6750Q37451519-52A40C1C-5C4C-4E16-B662-4176E45BD302Q37591761-2CF0FAD8-4669-4890-9071-363F058FA6B8Q37776261-F83C114E-6EA1-44BA-A80B-1F7AABBD76B5Q38040111-AA6768CC-A2B3-497F-8001-00428F818181Q38201930-EB870740-F632-4B75-96A9-796F9212FB4DQ38443986-E3ABCB82-3F64-405E-B9A3-C0829CACEDE1Q38483599-22EABDCE-B390-47DA-A597-3E2FFA136ACDQ38682624-0F89A35C-E2E4-4CF2-A0FE-FDCAB89E40C0Q38869522-91E5F365-AFCE-4237-92C5-F247B97FAE0BQ39127840-92B1491D-9FB1-42D0-BBCF-9AEC9FBAFCAEQ39835520-8B9B5B29-A0D1-4BA6-8795-3EC9C5839E2FQ40521021-DBB6890B-B8B6-42CF-95FC-EFB8336BA053Q41822487-9ACC78CC-CB01-453D-A66A-69F578B1D4ABQ42429569-DC072986-492D-4D8A-B96F-0C4531C7B4BFQ42534815-50DBA217-A5AB-4802-A51D-544DD1424DBDQ44902159-E20014E3-310D-4E54-AE5D-C1A8BDF1E903
P2860
Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@ast
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@en
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@nl
type
label
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@ast
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@en
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@nl
prefLabel
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@ast
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@en
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@nl
P1476
Efficacy and safety of injecta ...... nt of Dupuytren's contracture.
@en
P2093
Lawrence C Hurst
Marie A Badalamente
P304
P356
10.1016/J.JHSA.2007.04.002
P577
2007-07-01T00:00:00Z